BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34767735)

  • 1. RABL2A-CCDC34 Axis Promotes Sorafenib Resistance in Hepatocellular Carcinoma.
    Zhou M; Chen X; Bai H; Sun Y; Zhang Z; Li S; Wang X; Zeng M
    DNA Cell Biol; 2021 Nov; 40(11):1418-1427. PubMed ID: 34767735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells.
    Son Y; Shin NR; Kim SH; Park SC; Lee HJ
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BAFF/NFκB axis is crucial to interactions between sorafenib-resistant HCC cells and cancer-associated fibroblasts.
    Gao L; Morine Y; Yamada S; Saito Y; Ikemoto T; Tokuda K; Miyazaki K; Okikawa S; Takasu C; Shimada M
    Cancer Sci; 2021 Sep; 112(9):3545-3554. PubMed ID: 34159680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells.
    Gao L; Morine Y; Yamada S; Saito Y; Ikemoto T; Tokuda K; Takasu C; Miyazaki K; Shimada M
    PLoS One; 2021; 16(9):e0256755. PubMed ID: 34473785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [YAP regulates the proliferation and modifies the sensitivity to sorafenib in hepatocellular carcinoma cells].
    Guo LW; Shao GL; Luo J; Hao WY; Yao Z; Zheng JP
    Zhonghua Zhong Liu Za Zhi; 2018 Nov; 40(11):818-823. PubMed ID: 30481931
    [No Abstract]   [Full Text] [Related]  

  • 6. LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma.
    Sui C; Dong Z; Yang C; Zhang M; Dai B; Geng L; Lu J; Yang J; Xu M
    J Cell Mol Med; 2019 Sep; 23(9):6024-6033. PubMed ID: 31210410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
    Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
    Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of EGFR-KLF4 positive feedback loop results in acquired resistance to sorafenib in hepatocellular carcinoma.
    Pang L; Xu L; Yuan C; Li X; Zhang X; Wang W; Guo X; Ouyang Y; Qiao L; Wang Z; Liu K
    Mol Carcinog; 2019 Nov; 58(11):2118-2126. PubMed ID: 31465134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
    Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
    Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma.
    Yu J; Wang N; Gong Z; Liu L; Yang S; Chen GG; Lai PBS
    Oncogene; 2021 Jan; 40(3):492-507. PubMed ID: 33184472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
    Wu J; Chai H; Li F; Ren Q; Gu Y
    Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib.
    Niu LL; Cheng CL; Li MY; Yang SL; Hu BG; Chong CCN; Chan SL; Ren J; Chen GG; Lai PBS
    Cell Death Dis; 2018 Aug; 9(9):852. PubMed ID: 30154433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
    Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HBx Modulates Drug Resistance of Sorafenib-Resistant Hepatocellular Carcinoma Cells.
    Liu Y; Liu X; Luo M; Li Y; Li H
    Discov Med; 2023 Dec; 35(179):1035-1042. PubMed ID: 38058068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3.
    Kong H; Sun J; Zhang W; Zhang H; Li H
    Bioengineered; 2022 Feb; 13(2):3108-3121. PubMed ID: 35037556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3.
    Hu Z; Zhao Y; Li L; Jiang J; Li W; Mang Y; Gao Y; Dong Y; Zhu J; Yang C; Ran J; Li L; Zhang S
    Mol Biol Rep; 2023 Aug; 50(8):6399-6413. PubMed ID: 37326750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
    Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
    Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.